Scientists reprogram Patients' own cells to hunt deadly cancers

NCT ID NCT05296564

Summary

This early-stage trial tests whether a patient's own immune cells can be genetically modified to recognize and attack their cancer. The study is for adults with advanced cancers that have spread and express a specific marker called NY-ESO-1. Researchers will first find the safest dose, then see if the treatment causes tumors to shrink in patients who have already tried standard therapies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hadassah Medical Organization

    RECRUITING

    Jerusalem, 9112001, Israel

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.